Kailera Therapeutics, Inc.(KLRA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Kailera Therapeutics, Inc. (KLRA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. KLRA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of KLRA by reported 13-F value include BAIN CAPITAL INVESTORS, Bain Capital Life Sciences Investors, RTW INVESTMENTS, based on the most recent SEC filings. KLRA trades on the Nasdaq exchange and files with the SEC under CIK 2096997. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KLRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kailera Therapeutics, Inc. directly from SEC EDGAR.

Net Income

$-111.3M

Institutions holding KLRA

Institutional investors reporting a position in Kailera Therapeutics, Inc. on SEC Form 13F.
InstitutionSharesValueReported
BAIN CAPITAL INVESTORS26,255,581$578.4M2026-06-30
Bain Capital Life Sciences Investors22,583,268$497.5M2026-06-30
RTW INVESTMENTS10,776,820$237.4M2026-06-30
CANADA PENSION PLAN INVESTMENT BOARD7,304,688$160.9M2026-06-30
Atlas Venture Life Science Advisors5,171,282$113.9M2026-06-30
FMR3,970,865$87.5M2026-06-30
BlackRock3,928,604$86.5M2026-06-30
PRICE T ROWE ASSOCIATES3,534,410$77.9M2026-06-30
CITADEL ADVISORS3,240,787$71.4M2026-06-30
ADAGE CAPITAL PARTNERS GP, L.L.C.3,208,286$70.7M2026-06-30
SEC EDGAR: CIK 2096997 →
KLRA

Kailera Therapeutics, Inc.

KLRA
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-111.31M

EPS (Diluted)

Q2 2026
EDGAR

$-1.09

ROIC

Q2 2026
EDGAR

-43.4%

Top Institutional Holders

as of Q2 2026
$2.56B total
BAIN CAPITAL INVESTORS LLC
$578.41M--
Bain Capital Life Sciences Investors, LLC
$497.51M--
RTW INVESTMENTS, LP
$237.41M--
CANADA PENSION PLAN INVESTMENT BOARD
$160.92M--
Atlas Venture Life Science Advisors, LLC
$113.92M--
FMR LLC
$87.48M--
BlackRock, Inc.
$86.55M--
PRICE T ROWE ASSOCIATES INC /MD/
$77.86M--
CITADEL ADVISORS LLC
$71.39M--
ADAGE CAPITAL PARTNERS GP, L.L.C.
$70.68M--

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…